ProMisE分子分型系统在子宫内膜癌大型人群队列中的最终验证
本研究基于2003–2013年德国图宾根大学妇女医院452例子宫内膜癌回顾性队列,对ProMisE分子分型系统进行最终验证。ProMisE将肿瘤分为MMR-D、POLE、p53abn和p53wt四个预后不同的分子亚型,且诊断标本与手术标本一致性高(准确率0.91,κ 0.88)。ProMisE是无进展生存和疾病特异性生存的预后标志物,调整已知风险因素后仍显著。
要点
- ProMisE分型在452例子宫内膜癌中可重复区分四个预后不同的分子亚型。
- ProMisE是PFS(P=0.001)和DSS(P=0.03)的独立预后因素。
- 诊断标本与手术标本分型一致性高,准确率0.91,κ 0.88。
核心结论
- ProMisE分子分型系统已完成开发、确认和最终验证,可稳定区分四个预后不同的分子亚型。
- ProMisE是进展无生存和疾病特异性生存的预后标志物,调整已知风险因素后仍显著。
- 该分型系统可应用于诊断标本,有望指导手术方式和辅助治疗决策。
研究设计与样本
- 回顾性队列研究,纳入德国图宾根大学妇女医院2003–2013年治疗的子宫内膜癌患者。
- 共452例患者具有完整临床和分子数据可评估。
- 主要结局为总生存、疾病特异性生存和无进展生存。
主要发现
- 患者年龄范围29–93岁(中位65岁),87.8%为子宫内膜样组织学类型。
- 分级分布:G1 282例(62.4%)、G2 75例(16.6%)、G3 95例(21.0%)。
- 分期分布:IA期276例(61.1%)、IB期89例(19.7%)、II期26例(5.8%)、III/IV期61例(13.5%)。
- ProMisE分型结果:MMR-D 127例(28.1%)、POLE 42例(9.3%)、p53abn 55例(12.2%)、p53wt 228例(50.4%)。
- ProMisE是无进展生存(P=0.001)和疾病特异性生存(P=0.03)的预后标志物,调整已知风险因素后仍显著。
关键数值与推荐
- ProMisE分型在452例中分为MMR-D(28.1%)、POLE(9.3%)、p53abn(12.2%)和p53wt(50.4%)。
- 诊断标本与手术标本分型一致性:准确率0.91,κ 0.88。
- ProMisE对无进展生存的预后价值P=0.001,对疾病特异性生存P=0.03(调整后)。
临床怎么用
- ProMisE可应用于诊断标本(活检/刮宫标本),实现早期分子分型以辅助临床决策。
- 分型结果可帮助判断手术范围和是否需要辅助治疗。
- 基于IOM指南,该分型系统已准备好通过前瞻性临床试验进行临床评估。
局限性
- 研究为单中心回顾性队列设计。
- 样本来自单一机构2003–2013年治疗的患者。
- 尚未通过前瞻性临床试验验证临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have previously developed and confirmed a pragmatic molecular classifier for endometrial cancers; ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). Inspired by the Cancer Genome Atlas, ProMisE identifies four prognostically distinct molecular subtypes and can be applied to diagnostic specimens (biopsy/curettings) enabling earlier informed decision-making. We have strictly adhered to the Institute of Medicine (IOM) guidelines for the development of genomic biomarkers, and herein present the final validation step of a locked-down classifier before clinical application. PATIENTS AND METHODS: We assessed a retrospective cohort of women from the Tübingen University Women's Hospital treated for endometrial carcinoma between 2003 and 2013. Primary outcomes of overall, disease-specific, and progression-free survival were evaluated for clinical, pathological, and molecular features. RESULTS: Complete clinical and molecular data were evaluable from 452 women. Patient age ranged from 29 to 93 (median 65) years, and 87.8% cases were endometrioid histotype. Grade distribution included 282 (62.4%) G1, 75 (16.6%) G2, and 95 (21.0%) G3 tumors. 276 (61.1%) patients had stage IA disease, with the remaining stage IB [89 (19.7%)], stage II [26 (5.8%)], and stage III/IV [61 (13.5%)]. ProMisE molecular classification yielded 127 (28.1%) MMR-D, 42 (9.3%) POLE, 55 (12.2%) p53abn, and 228 (50.4%) p53wt. ProMisE was a prognostic marker for progression-free (P = 0.001) and disease-specific (P = 0.03) survival even after adjusting for known risk factors. Concordance between diagnostic and surgical specimens was highly favorable; accuracy 0.91, κ 0.88. DISCUSSION: We have developed, confirmed, and now validated a pragmatic molecular classification tool (ProMisE) that provides consistent categorization of tumors and identifies four distinct prognostic molecular subtypes. ProMisE can be applied to diagnostic samples and thus could be used to inform surgical procedure(s) and/or need for adjuvant therapy. Based on the IOM guidelines this classifier is now ready for clinical evaluation through prospective clinical trials.
引用
- Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018. PMID: 29432521. doi:10.1093/annonc/mdy058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。